# Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide

> **NCT07295873** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Beijing Continent Pharmaceutical Co, Ltd.** · enrollment: 64 (estimated)

## Conditions studied

- Chronic Hepatitis B Liver Fibrosis
- DDI (Drug-Drug Interaction)

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Tenofovir Disoproxil Fumarate（TDF）
- **DRUG:** Tenofovir alafenamide（TAF）
- **DRUG:** Tenofovir Amibufenamide(TMF)

## Key facts

- **NCT ID:** NCT07295873
- **Lead sponsor:** Beijing Continent Pharmaceutical Co, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07295873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07295873, "Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT07295873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*